Lauren M Cohee1, Ingrid Peterson1, Andrea G Buchwald1, Jenna E Coalson2, Clarissa Valim3, Moses Chilombe4, Andrew Ngwira4, Andy Bauleni4, Sarah Schaffer-DeRoo5, Karl B Seydel6, Mark L Wilson2, Terrie E Taylor6, Don P Mathanga4, Miriam K Laufer1. 1. Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. 2. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA. 3. Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA. 4. Malaria Alert Centre, Kamuzu University of Health Sciences, Blantyre, Malawi. 5. University of Maryland School of Medicine, Baltimore, Maryland, USA. 6. College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, USA.
Abstract
BACKGROUND: In areas highly endemic for malaria, Plasmodium falciparum infection prevalence peaks in school-age children, adversely affecting health and education. School-based intermittent preventive treatment reduces this burden but concerns about cost and widespread use of antimalarial drugs limit enthusiasm for this approach. School-based screening and treatment is an attractive alternative. In a prospective cohort study, we evaluated the impact of school-based screening and treatment on the prevalence of P. falciparum infection and anemia in 2 transmission settings. METHODS: We screened 704 students in 4 Malawian primary schools for P. falciparum infection using rapid diagnostic tests (RDTs), and treated students who tested positive with artemether-lumefantrine. We determined P. falciparum infection by microscopy and quantitative polymerase chain reaction (qPCR), and hemoglobin concentrations over 6 weeks in all students. RESULTS: Prevalence of infection by RDT screening was 37% (9%-64% among schools). An additional 9% of students had infections detected by qPCR. Following the intervention, significant reductions in infections were detected by microscopy (adjusted relative reduction [aRR], 48.8%; P < .0001) and qPCR (aRR, 24.5%; P < .0001), and in anemia prevalence (aRR, 30.8%; P = .003). Intervention impact was reduced by infections not detected by RDT and new infections following treatment. CONCLUSIONS: School-based screening and treatment reduced P. falciparum infection and anemia. This approach could be enhanced by repeating screening, using more-sensitive screening tests, and providing longer-acting drugs. CLINICAL TRIALS REGISTRATION: NCT04858087.
BACKGROUND: In areas highly endemic for malaria, Plasmodium falciparum infection prevalence peaks in school-age children, adversely affecting health and education. School-based intermittent preventive treatment reduces this burden but concerns about cost and widespread use of antimalarial drugs limit enthusiasm for this approach. School-based screening and treatment is an attractive alternative. In a prospective cohort study, we evaluated the impact of school-based screening and treatment on the prevalence of P. falciparum infection and anemia in 2 transmission settings. METHODS: We screened 704 students in 4 Malawian primary schools for P. falciparum infection using rapid diagnostic tests (RDTs), and treated students who tested positive with artemether-lumefantrine. We determined P. falciparum infection by microscopy and quantitative polymerase chain reaction (qPCR), and hemoglobin concentrations over 6 weeks in all students. RESULTS: Prevalence of infection by RDT screening was 37% (9%-64% among schools). An additional 9% of students had infections detected by qPCR. Following the intervention, significant reductions in infections were detected by microscopy (adjusted relative reduction [aRR], 48.8%; P < .0001) and qPCR (aRR, 24.5%; P < .0001), and in anemia prevalence (aRR, 30.8%; P = .003). Intervention impact was reduced by infections not detected by RDT and new infections following treatment. CONCLUSIONS: School-based screening and treatment reduced P. falciparum infection and anemia. This approach could be enhanced by repeating screening, using more-sensitive screening tests, and providing longer-acting drugs. CLINICAL TRIALS REGISTRATION: NCT04858087.
Authors: Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia Journal: N Engl J Med Date: 2012-11-09 Impact factor: 91.245
Authors: Aaron M Samuels; Nobert Awino Odero; Wycliffe Odongo; Kephas Otieno; Vincent Were; Ya Ping Shi; Tony Sang; John Williamson; Ryan Wiegand; Mary J Hamel; S Patrick Kachur; Laurence Slutsker; Kim A Lindblade; Simon K Kariuki; Meghna R Desai Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 20.999
Authors: Lauren M Cohee; Charles Opondo; Siân E Clarke; Katherine E Halliday; Jorge Cano; Andrea G Shipper; Breanna Barger-Kamate; Abdoulaye Djimde; Seybou Diarra; Aditi Dokras; Moses R Kamya; Pascal Lutumba; Alioune Badara Ly; Joaniter I Nankabirwa; J Kiambo Njagi; Hamma Maiga; Catherine Maiteki-Sebuguzi; Junior Matangila; George Okello; Fabian Rohner; Natalie Roschnik; Saba Rouhani; Mahamadou S Sissoko; Sarah G Staedke; Mahamadou A Thera; Elizabeth L Turner; J P Van Geertruyden; Michael B Zimmerman; Matthew C H Jukes; Simon J Brooker; Elizabeth Allen; Miriam K Laufer; R Matthew Chico Journal: Lancet Glob Health Date: 2020-10-22 Impact factor: 26.763
Authors: Doris P Yimgang; Andrea G Buchwald; Jenna E Coalson; Jenny A Walldorf; Andy Bauleni; Atupele Kapito-Tembo; Don P Mathanga; Terrie E Taylor; Miriam K Laufer; Lauren M Cohee Journal: Am J Trop Med Hyg Date: 2021-01-04 Impact factor: 2.345
Authors: Joaniter Nankabirwa; Bonnie Wandera; Noah Kiwanuka; Sarah G Staedke; Moses R Kamya; Simon J Brooker Journal: Am J Trop Med Hyg Date: 2013-04-15 Impact factor: 2.345
Authors: Siân E Clarke; Matthew C H Jukes; J Kiambo Njagi; Lincoln Khasakhala; Bonnie Cundill; Julius Otido; Christopher Crudder; Benson B A Estambale; Simon Brooker Journal: Lancet Date: 2008-07-12 Impact factor: 79.321
Authors: Joaniter I Nankabirwa; Bonnie Wandera; Pauline Amuge; Noah Kiwanuka; Grant Dorsey; Philip J Rosenthal; Simon J Brooker; Sarah G Staedke; Moses R Kamya Journal: Clin Infect Dis Date: 2014-03-12 Impact factor: 9.079
Authors: Caroline W Gitonga; Tansy Edwards; Peris N Karanja; Abdisalan M Noor; Robert W Snow; Simon J Brooker Journal: Trop Med Int Health Date: 2012-05-11 Impact factor: 2.622